164 related articles for article (PubMed ID: 34822853)
41. THE RAP STUDY, REPORT TWO: The Regional Distribution of Macular Neovascularization Type 3, a Novel Insight Into Its Etiology.
Haj Najeeb B; Deak G; Schmidt-Erfurth U; Gerendas BS
Retina; 2020 Dec; 40(12):2255-2262. PubMed ID: 32032256
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization.
Li Y; Liu X; Zhou T; Kelley MR; Edwards P; Gao H; Qiao X
Redox Biol; 2014; 2():485-94. PubMed ID: 24624338
[TBL] [Abstract][Full Text] [Related]
43. Antiangiogenic effect of betaine on pathologic retinal neovascularization via suppression of reactive oxygen species mediated vascular endothelial growth factor signaling.
Park SW; Jun HO; Kwon E; Yun JW; Kim JH; Park YJ; Kang BC; Kim JH
Vascul Pharmacol; 2017 Mar; 90():19-26. PubMed ID: 27473515
[TBL] [Abstract][Full Text] [Related]
44. Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models.
Giddabasappa A; Lalwani K; Norberg R; Gukasyan HJ; Paterson D; Schachar RA; Rittenhouse K; Klamerus K; Mosyak L; Eswaraka J
Exp Eye Res; 2016 Apr; 145():373-379. PubMed ID: 26927930
[TBL] [Abstract][Full Text] [Related]
45. Isoliquiritigenin from licorice root suppressed neovascularisation in experimental ocular angiogenesis models.
Jhanji V; Liu H; Law K; Lee VY; Huang SF; Pang CP; Yam GH
Br J Ophthalmol; 2011 Sep; 95(9):1309-15. PubMed ID: 21719569
[TBL] [Abstract][Full Text] [Related]
46. Pharmacology study of a chimeric decoy receptor trap fusion protein on retina neovascularization by dual blockage of VEGF and FGF-2.
Jiang J; Xu K; Wang L; Xin W; Zhao G; Huang M; Li S; Luan X; Fang J
Eur J Pharm Sci; 2018 Aug; 121():251-259. PubMed ID: 29715501
[TBL] [Abstract][Full Text] [Related]
47. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
48. A New Era in Reducing Treatment Burden in Retinal Disease.
Retina; 2021 Apr; 41(Suppl 1):S1-S12. PubMed ID: 33787534
[No Abstract] [Full Text] [Related]
49. Outcomes by Baseline Choroidal Neovascularization Features in Age-Related Macular Degeneration: A Post Hoc Analysis of the VIEW Studies.
Steinle NC; Du W; Gibson A; Saroj N
Ophthalmol Retina; 2021 Feb; 5(2):141-150. PubMed ID: 32652314
[TBL] [Abstract][Full Text] [Related]
50. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
51. An arylidene-thiazolidinedione derivative, GPU-4, without PPARγ activation, reduces retinal neovascularization.
Nakamura S; Hayashi K; Takizawa H; Murase T; Tsuruma K; Shimazawa M; Kakuta H; Nagasawa H; Hara H
Curr Neurovasc Res; 2011 Feb; 8(1):25-34. PubMed ID: 21208163
[TBL] [Abstract][Full Text] [Related]
52. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of APE1/Ref-1 for Neovascular Eye Diseases: From Biology to Therapy.
Hartman GD; Lambert-Cheatham NA; Kelley MR; Corson TW
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638620
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of Hypoxia-Inducible Factor-1α and Vascular Endothelial Growth Factor by Chrysin in a Rat Model of Choroidal Neovascularization.
Song JH; Moon KY; Lee SC; Kim SS
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325771
[TBL] [Abstract][Full Text] [Related]
55. A Sema3C Mutant Resistant to Cleavage by Furin (FR-Sema3C) Inhibits Choroidal Neovascularization.
Toledano S; Lu H; Palacio A; Ziv K; Kessler O; Schaal S; Neufeld G; Barak Y
PLoS One; 2016; 11(12):e0168122. PubMed ID: 28036336
[TBL] [Abstract][Full Text] [Related]
56. Apolipoprotein E2 and E3, but Not E4, Promote Retinal Pathologic Neovascularization.
Masuda T; Shimazawa M; Hashimoto Y; Kojima A; Nakamura S; Suemori S; Mochizuki K; Kawakami H; Kawase K; Hara H
Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):1208-1217. PubMed ID: 28241308
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization.
Crespo-Garcia S; Corkhill C; Roubeix C; Davids AM; Kociok N; Strauss O; Joussen AM; Reichhart N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):4997-5006. PubMed ID: 28979997
[TBL] [Abstract][Full Text] [Related]
58. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
[TBL] [Abstract][Full Text] [Related]
59. Repurposing bortezomib for choroidal neovascularization treatment via antagonizing VEGF-A and PDGF-D mediated signaling.
Liu Y; Feng M; Cai J; Li S; Dai X; Shan G; Wu S
Exp Eye Res; 2021 Mar; 204():108446. PubMed ID: 33476605
[TBL] [Abstract][Full Text] [Related]
60. Joint Antiangiogenic Effect of ATN-161 and Anti-VEGF Antibody in a Rat Model of Early Wet Age-Related Macular Degeneration.
Wang WQ; Wang FH; Qin WX; Liu HY; Lu B; Chung C; Zhu J; Gu Q; Shi W; Wen C; Wu F; Zhang K; Sun XD
Mol Pharm; 2016 Sep; 13(9):2881-90. PubMed ID: 27089240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
